Drugs / CNTX-3001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07122453 | Mar 2026 → Jan 2027 expected | — | Centrexion Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CNTX-3001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07122453 ↗ |
| Modality | Small molecule | “CNTX-3001 is a novel, non-opioid small molecule” NCT07122453 ↗ |
| Route | Intrathecal | “given into the intrathecal space by lumbar puncture” NCT07122453 ↗ |